Ray Dalio Neurocrine Biosciences Inc Transaction History
Bridgewater Associates, LP
- $21.1 Billion
- Q4 2024
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bridgewater Associates, LP holds 332,598 shares of NBIX stock, worth $31.6 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
332,598
Previous 135,186
146.03%
Holding current value
$31.6 Million
Previous $15.6 Million
191.71%
% of portfolio
0.22%
Previous 0.09%
Shares
13 transactions
Others Institutions Holding NBIX
# of Institutions
656Shares Held
95.3MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.35 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$960 Million0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$464 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$286 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$241 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $9.08B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...